Retatrutide (LY3437943) — Triple Incretin Receptor Agonist
Also Known AsLY3437943 · Reta · GGG tri-agonist
Developed by Eli Lilly as the first triple incretin receptor agonist (GLP-1R/GIPR/GCGR). Designed to simultaneously activate all three incretin and glucagon pathways for maximal metabolic benefit.
How Retatrutide Works
GLP-1 Receptor Agonism
Activates GLP-1 receptors for appetite suppression, glucose-dependent insulin secretion, and gastric emptying delay — the same pathway as semaglutide.
GIP Receptor Agonism
Activates glucose-dependent insulinotropic polypeptide receptors, enhancing insulin sensitivity and promoting fat oxidation in adipose tissue. The GIP component distinguishes it from pure GLP-1 agonists and contributes to improved tolerability.
Glucagon Receptor Agonism
Uniquely activates the glucagon receptor, increasing hepatic fat oxidation, energy expenditure via thermogenesis, and amino acid-driven satiety. This is the component absent from all other approved metabolic peptides.
Published Research
Obesity
StrongPhase 2 data published in NEJM demonstrated up to 24.2% mean body weight reduction at the highest dose (12mg) over 48 weeks — the largest weight reduction ever observed in a clinical obesity trial at time of publication. Phase 3 (TRIUMPH program) is ongoing.
Type 2 Diabetes
ModeratePhase 2 data demonstrated HbA1c reductions of up to 2.02% at 36 weeks, with dose-dependent glycemic improvements and substantial weight loss across all dose groups.
NAFLD/Metabolic Liver Disease
EmergingPreclinical and early clinical data suggest exceptional effects on hepatic steatosis, likely driven by the glucagon receptor component which directly promotes hepatic fat oxidation. This represents a key differentiator from GLP-1-only agents.
Safety Profile
Phase 2 adverse event profile similar to other incretin-based therapies: nausea, diarrhea, vomiting, decreased appetite. Dose titration mitigates GI effects. The glucagon receptor component raises theoretical concerns about hyperglycemia in non-diabetic populations, though not observed in trials. Phase 3 safety data pending.
Handling & Storage
Reconstitute lyophilized retatrutide with bacteriostatic water. Store reconstituted solution at 2-8°C. Lyophilized powder stable at -20°C.
Peer-Reviewed Literature
- 1
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
- 2
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias JP, Jastreboff AM, et al.
Retatrutide FAQ
What is retatrutide?
Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It represents the most advanced multi-receptor metabolic compound in clinical development.
How does retatrutide compare to semaglutide?
Retatrutide targets three receptors (GLP-1R, GIPR, GCGR) compared to semaglutide's single receptor (GLP-1R). Phase 2 clinical data showed retatrutide achieved ~24% mean weight reduction vs. ~17% for semaglutide, likely due to additive effects from GIP-mediated fat oxidation and glucagon-mediated hepatic metabolism and thermogenesis.
What phase of clinical development is retatrutide in?
As of 2024-2025, retatrutide is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program, which includes studies for obesity and type 2 diabetes. Phase 2 results published in the New England Journal of Medicine (2023) demonstrated record-setting weight reduction.
Retatrutide Products
All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide
Entry dose of the most powerful weight loss peptide in existence — starter Retatrutide for those beginning the triple-agonist protocol that's making Ozempic look like last gen.
- Triple-agonist technology — next generation beyond Ozempic
- Starter dose for the most effective weight loss peptide available
Explore Related Research
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)
AOD 9604
5mgThe fat-burning fragment of growth hormone — targets and destroys stubborn body fat (especially belly fat) without touching muscle, blood sugar, or hormone levels.
- Burns fat without affecting blood sugar or growth hormone levels
- Targets stubborn belly fat specifically
Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.